DS-7113b injection phase II/III study An open label and extension study of DS-7113 injection in patients with cancer pain (intravenous administration)

Trial Profile

DS-7113b injection phase II/III study An open label and extension study of DS-7113 injection in patients with cancer pain (intravenous administration)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 27 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 09 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top